Our patients are the heart of our company, and they, along with their families, friends and caregivers, are just as much members of the Imvax team. Patient care is our priority, and it is our joint effort and mission to change the course of cancer treatment and transform cancer outcomes.
At Imvax, we’re focused on the development of novel immunotherapies for the treatment of malignant gliomas (a specific type of brain tumor) and other cancers with unmet medical needs. As a company, we are obligated to ensure the safe and proper use of our investigational therapies and to provide access at the appropriate time, in the right manner and under the guidance of regulatory authorities, specifically the US Food and Drug Administration (FDA).
At this time, Imvax, has no actively recruiting clinical trials. We will be initiating the ImmuneSense study (NCT04485949), a randomized, placebo-controlled Phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma, in the fourth quarter of 2021. For more information about that trial, visit ClinicalTrials.gov.